Genital herpes rising in England, despite overall drop in STIs

England's public health system has documented a significant and unexpected rise in genital herpes infections throughout 2024, even as overall sexually transmitted infection rates have declined across the country. This reversal in the herpes trajectory represents a notable divergence from the broader STI landscape and has prompted urgent scrutiny from epidemiologists and sexual health specialists working within the National Health Service. The increase, recorded across multiple regions with particular concentration in urban centres, underscores a complex pattern of disease transmission that defies simple explanations and challenges assumptions about infection prevention in a population with improved sexual health literacy. This development arrives at a moment when England's sexual health infrastructure has been under sustained pressure from budget constraints, reduced clinic capacity, and declining access to preventative services in many local authorities.

The context surrounding this genital herpes surge becomes clearer when examined against the historical trajectory of sexual health in England. Over the past decade, most STI categories have experienced downward pressure due to improved condom use, earlier treatment protocols, and expanded access to testing through digital platforms and community settings. However, genital herpes has consistently presented a unique epidemiological challenge because the virus remains dormant in nerve cells indefinitely, meaning individuals can transmit the infection even during asymptomatic periods when they may not realise they carry the virus. This characteristic distinguishes herpes from bacterial STIs such as chlamydia or gonorrhoea, where absence of symptoms often correlates with reduced transmission risk. The timing of this reversal matters substantially because it occurs amid a broader contraction in sexual health services, with many local authorities reporting reduced funding for sexual health clinics and fewer health advisors available for contact tracing and patient education, factors that directly impact the ability to identify and manage herpes transmission chains.

Data collection efforts in 2024 have revealed concrete trends that demand careful analysis. Health authorities documented increased numbers of first-episode genital herpes diagnoses across testing facilities, with young people aged 16 to 24 representing a disproportionate share of new cases, indicating that awareness and prevention messaging may not be reaching this demographic effectively. The prevalence of recurrent infections has also climbed, suggesting that existing cases are becoming more symptomatic or that individuals are finally seeking diagnosis for previously undetected infections. Concurrently, testing rates for herpes specifically have not risen proportionally to infection rates, meaning the actual burden of disease likely exceeds reported figures and indicates a significant reservoir of undiagnosed cases circulating within the population. This diagnostic gap carries particular weight because individuals unaware of their herpes status cannot take protective measures such as suppressive antiviral therapy or inform sexual partners, creating ongoing transmission opportunities.

The health system implications of rising genital herpes extend far beyond infection statistics and touch upon immediate patient management challenges. Individuals experiencing primary herpes infection endure significant physical discomfort and psychological distress, with some experiencing debilitating symptoms that impact work attendance and social functioning during acute episodes. The emotional burden of herpes diagnosis remains substantial despite improvements in public understanding, with many newly diagnosed patients struggling with stigma and relationship concerns that warrant specialist counselling services increasingly stretched across already overburdened sexual health clinics. Treatment protocols, while effective through antiviral medications such as aciclovir and valaciclovir, require sustained medication adherence across extended periods, and access to these treatments through NHS prescribing has become inconsistent as general practices face their own resource constraints. Furthermore, the potential complications including neonatal herpes risk for pregnant women and increased susceptibility to other STIs during herpes outbreaks create cascading health system demands that extend beyond straightforward antiviral dispensing into obstetric and infectious disease services.

This genital herpes resurgence illuminates a broader pattern affecting sexual health infrastructure across England and signals fundamental vulnerabilities in disease prevention capacity. The decline in overall STI rates masks significant internal variation, with certain infections becoming entrenched within specific demographic groups while others remain stubbornly resistant to intervention despite technological advances and treatment options. Genital herpes, occupying a unique position as a chronic viral infection with episodic transmission risk, has effectively become a sentinel indicator of sexual health system adequacy precisely because it reveals the limits of current prevention and management strategies. The data suggests that population-level sexual health outcomes depend not merely on individual knowledge or behaviour but on sustained institutional investment in surveillance, accessible testing, responsive clinical services, and quality patient education that reaches diverse populations effectively. This recognition forces recalibration of how England measures sexual health success and indicates that improving overall STI statistics may obscure deteriorating outcomes for specific infections requiring distinct intervention approaches.

Stakeholders and health authorities face critical junctures in the coming months that will shape herpes management outcomes. The UK Health Security Agency and local authority sexual health commissioners must define measurable targets for herpes case identification and suppression across 2025 and 2026, establishing baseline surveillance protocols that capture both diagnosed and estimated disease burden. Simultaneously, the Society for Sexual Health Advisers and clinical microbiology services require explicit resource allocations to expand testing capacity in primary care settings and community venues where younger people access services, recognising that traditional sexual health clinics no longer represent the primary gateway for many young adults. Healthcare providers should anticipate that suppressive antiviral therapy prescribing will need to expand significantly, requiring primary care education programmes to build clinical confidence in managing chronic herpes outside specialist settings. Observers should monitor whether the Department of Health and Social Care acknowledges genital herpes trends in forthcoming sexual health policy documents and whether it translates acknowledgment into concrete funding decisions that rebuild clinical capacity lost over the previous decade of austerity.